[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI0409366A - compostos de pirimido - Google Patents

compostos de pirimido

Info

Publication number
BRPI0409366A
BRPI0409366A BRPI0409366-6A BRPI0409366A BRPI0409366A BR PI0409366 A BRPI0409366 A BR PI0409366A BR PI0409366 A BRPI0409366 A BR PI0409366A BR PI0409366 A BRPI0409366 A BR PI0409366A
Authority
BR
Brazil
Prior art keywords
compounds
pyrimidine compounds
kdr
colon
lung
Prior art date
Application number
BRPI0409366-6A
Other languages
English (en)
Inventor
Yi Chen
Apostolos Dermatakis
Jin-Jun Liu
Kin-Chun Luk
Christophe Michoud
Pamela Loreen Rossman
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0409366A publication Critical patent/BRPI0409366A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"COMPOSTOS DE PIRIMIDO". A presente invenção refere-se a novos compostos de pirimido da fórmula: que são inibidores seletivos das cinases KDR e FGFR. Esses compostos e seus sais farmaceuticamente aceitáveis são agentes antiproliferativos usados no tratamento ou controle de tumores sólidos, em particular, tumores de mama, cólon, pulmão e próstata. Também descritas são composições farmacêuticas contendo esses compostos e o uso para tratamento de câncer.
BRPI0409366-6A 2003-04-10 2004-04-01 compostos de pirimido BRPI0409366A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46169403P 2003-04-10 2003-04-10
PCT/EP2004/003447 WO2004089955A1 (en) 2003-04-10 2004-04-01 Pyrimido compounds

Publications (1)

Publication Number Publication Date
BRPI0409366A true BRPI0409366A (pt) 2006-04-25

Family

ID=33159829

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409366-6A BRPI0409366A (pt) 2003-04-10 2004-04-01 compostos de pirimido

Country Status (11)

Country Link
US (1) US7115740B2 (pt)
EP (1) EP1615928A1 (pt)
JP (1) JP2006522756A (pt)
KR (2) KR20050111636A (pt)
CN (1) CN100497339C (pt)
AU (1) AU2004228155A1 (pt)
BR (1) BRPI0409366A (pt)
CA (1) CA2521124A1 (pt)
MX (1) MXPA05010765A (pt)
RU (1) RU2350617C2 (pt)
WO (1) WO2004089955A1 (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0413005A (pt) * 2003-07-29 2006-09-26 Irm Llc compostos e composições como inibidores da proteìna cinase
EP1809608A4 (en) * 2004-10-28 2009-11-04 Merck & Co Inc PYRIMIDINES AND CHINOLINES THAT ACTIVATE AS REINFORCING SUBSTANCES OF METABOTROPIC GLUTAMATE RECEPTORS
BRPI0619052A2 (pt) * 2005-11-28 2011-09-20 Hoffmann La Roche compostos, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de diacilglicerol aciltransferase, e seu uso
WO2007088014A1 (en) 2006-01-31 2007-08-09 F. Hoffmann-La Roche Ag 7h-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors
EP2376494A4 (en) 2008-12-12 2012-07-11 Msd Kk DIHYDROPYRIMIDOPIRYMIDINE DERIVATIVES
AU2009325398A1 (en) 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivative
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
EP2401613A2 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8642834B2 (en) 2009-02-27 2014-02-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
HUE064883T2 (hu) * 2011-04-22 2024-04-28 Signal Pharm Llc Szubsztituált diaminokarboxamid- és diaminokarbonitril-pirimidinek, azok készítményei és azokkal történõ kezelési eljárások
WO2013018733A1 (ja) 2011-07-29 2013-02-07 富士フイルム株式会社 １，５－ナフチリジン誘導体又はその塩
GB201204384D0 (en) 2012-03-13 2012-04-25 Univ Dundee Anti-flammatory agents
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US9611267B2 (en) 2012-06-13 2017-04-04 Incyte Holdings Corporation Substituted tricyclic compounds as FGFR inhibitors
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
CA2907243C (en) 2013-03-15 2021-12-28 Celgene Avilomics Research, Inc. Substituted dihydropyrimidopyrimidinone compounds and pharmaceutical compositions thereof use fgfr4 inhibitor
CN105307657B (zh) 2013-03-15 2020-07-10 西建卡尔有限责任公司 杂芳基化合物和其用途
US9321786B2 (en) 2013-03-15 2016-04-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP2986610B9 (en) 2013-04-19 2018-10-17 Incyte Holdings Corporation Bicyclic heterocycles as fgfr inhibitors
WO2016014542A1 (en) 2014-07-21 2016-01-28 Dana-Farber Cancer Institute, Inc. Imidazolyl kinase inhibitors and uses thereof
EP3172213B1 (en) 2014-07-21 2021-09-22 Dana-Farber Cancer Institute, Inc. Macrocyclic kinase inhibitors and uses thereof
WO2016023014A2 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Uses of salt-inducible kinase (sik) inhibitors
ES2914072T3 (es) 2014-08-18 2022-06-07 Eisai R&D Man Co Ltd Sal de derivado de piridina monocíclico y su cristal
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
ES2895769T3 (es) 2015-02-20 2022-02-22 Incyte Corp Heterociclos bicíclicos como inhibidores de FGFR
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
ES2920823T3 (es) * 2016-07-05 2022-08-10 Broad Inst Inc Inhibidores bicíclicos de la urea quinasa y usos de los mismos
WO2018053373A1 (en) 2016-09-16 2018-03-22 The General Hospital Corporation Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis
US11285158B2 (en) 2017-02-28 2022-03-29 The General Hospital Corporation Uses of pyrimidopyrimidinones as SIK inhibitors
EP3589634A4 (en) * 2017-03-03 2020-08-12 Auckland Uniservices Limited FGFR KINASE INHIBITORS AND PHARMACEUTICAL USES
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN109384790B (zh) * 2017-08-08 2022-05-10 药捷安康(南京)科技股份有限公司 成纤维细胞生长因子受体抑制剂及其用途
CN109836427B (zh) * 2017-11-29 2022-04-15 暨南大学 嘧啶并嘧啶酮类化合物及其应用
CA3091153A1 (en) 2018-03-28 2019-10-03 Eisai R&D Management Co., Ltd. Therapeutic agent for hepatocellular carcinoma
CN112566912A (zh) 2018-05-04 2021-03-26 因赛特公司 Fgfr抑制剂的盐
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
EA202191800A1 (ru) * 2018-12-27 2021-09-13 Ле Лаборатуар Сервье Сас Азагетеробициклические ингибиторы мат2а и способы их применения для нацеливания на рак
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
GB201908511D0 (en) 2019-06-13 2019-07-31 Adorx Therapeutics Ltd Hydroxamate compounds
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP2022552324A (ja) 2019-10-14 2022-12-15 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての二環式複素環
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
KR20240115979A (ko) 2021-11-08 2024-07-26 프로젠토스 테라퓨틱스, 인크. 혈소판-유래 성장 인자 수용체(pdgfr) 알파 억제제 및 이의 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2949466A (en) * 1958-03-04 1960-08-16 Parke Davis & Co Pyrimidine compounds and means of producing the same
NL6704601A (pt) * 1966-04-06 1967-10-09
US4425346A (en) * 1980-08-01 1984-01-10 Smith And Nephew Associated Companies Limited Pharmaceutical compositions
JPS60226882A (ja) * 1984-04-24 1985-11-12 Nippon Zoki Pharmaceut Co Ltd 新規ピリミドピリミジン誘導体
WO1998024432A2 (en) 1996-12-05 1998-06-11 Sugen, Inc. Use of indolinone compounds as modulators of protein kinases
TR200003429T2 (tr) 1998-05-26 2001-07-23 Warner-Lambert Company Hücresel çoğalma inhibitörleri olarak bisiklik pirimidinler ve bisiklik 3,4-dihidropirimidinler.
DE69920732T2 (de) 1998-10-23 2006-02-23 F. Hoffmann-La Roche Ag Bicyclische stickstoffheteroaryl verbindungen
ATE353329T1 (de) * 1999-10-21 2007-02-15 Hoffmann La Roche Heteroalkylamino-substituierte bicyclische stickstoffheterocyclen
ES2277858T3 (es) * 1999-10-21 2007-08-01 F. Hoffmann-La Roche Ag Heterociclos de nitrogeno biciclicos alquilamino sustituidos como inhibidores de proteina kinasa p38.
AR030053A1 (es) 2000-03-02 2003-08-13 Smithkline Beecham Corp 1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas
CA2420286A1 (en) 2000-08-31 2002-03-07 F. Hoffmann-La Roche Ag 7-oxo pyridopyrimidines as inhibitors of a cellular proliferation
BRPI0307057B8 (pt) 2002-01-22 2021-05-25 Warner Lambert Co compostos 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas
US7196090B2 (en) * 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
WO2004041285A1 (en) * 2002-10-31 2004-05-21 Amgen Inc. Antiinflammation agents

Also Published As

Publication number Publication date
WO2004089955A1 (en) 2004-10-21
RU2350617C2 (ru) 2009-03-27
KR20050111636A (ko) 2005-11-25
CN1809569A (zh) 2006-07-26
JP2006522756A (ja) 2006-10-05
RU2005134686A (ru) 2006-07-27
EP1615928A1 (en) 2006-01-18
US7115740B2 (en) 2006-10-03
KR20070087053A (ko) 2007-08-27
US20040204427A1 (en) 2004-10-14
AU2004228155A1 (en) 2004-10-21
KR100864393B1 (ko) 2008-10-20
CN100497339C (zh) 2009-06-10
MXPA05010765A (es) 2005-12-12
CA2521124A1 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
BRPI0409366A (pt) compostos de pirimido
BR0315912A (pt) Compostos pirimìdicos com atividade antiproliferativa (ii)
TW200407326A (en) Pyrimido compounds having antiproliferative activity
BR0317480A (pt) Derivados de piridino[2,3-d]pirimidina como inibidores kdr e fgfr seletivos
BRPI0511975A (pt) pirazolopirimidinas
BR0206496A (pt) Diaminotiazóis
JO2248B1 (en) Pirazolobenzodiazepines
IL191832A (en) Pyridiazinone compounds and their use in the preparation of drugs for the treatment of tumors
RS20050522A (en) Protein kinase inhibiting tricyclic compounds that increase the effects of anti-neoplastic agents and therapeutic radiation
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
BR0308030A (pt) Derivados de 5-feniltiazol e uso como inibidores de pi3 cinase
BRPI0407834A (pt) composto, processo para a manufatura do mesmo, composição, processo para a manufatura da mesma, método de tratamento ou prevenção de um distúrbio mediado por proteìna quinase em um indivìduo, uso de um composto, ensaio para determinar a atividade dos compostos, e, método de inibição da atividade ou função de uma proteìna quinase
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
DE50310516D1 (de) Fredericamycin-derivate
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
BRPI0821743B8 (pt) derivados de piridazinona, e seu uso
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
CY1108061T1 (el) Παραγωγα κιναζολινης ως src αναστολεις κινασης τυροσινης
BR0310081A (pt) Diaminotiazóis úteis como inibidores seletivos de cdk4
ATE287886T1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer
EA200501233A1 (ru) 4-аминопиримидин-5-он
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
DE602007010038D1 (de) Pyrimidylderivate als proteinkinaseinhibitoren
BRPI0520482A2 (pt) amidas do ácido 4-amino-tieno [3,2-c] piridina-7-carboxìlico
BRPI0815334A2 (pt) derivados de pirazolo[3,4-d]-piramidina como agentes antiproliferativos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.